Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, May 22, 2010

Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.



CONCLUSION:
Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.